Biomarker Development in LGMD2i (MLB-01-001)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04202627|
Recruitment Status : Completed
First Posted : December 17, 2019
Last Update Posted : October 26, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
|Muscular Dystrophies Limb Girdle Muscular Dystrophy|
Limb Girdle Muscular Dystrophy (LGMD) 2i is an autosomal recessive form of LGMD that is due to missense mutations in the Fukutin-related protein (FKRP) gene. Patients develop progressive proximal muscle weakness that leads to loss of ambulation. Patients will also commonly develop a cardiomyopathy and respiratory compromise.
There are promising new therapies that have been developed and as a result therapeutic trials are approaching.
The rationale for this study is to define appropriate COAs for LGMD2i, which will facilitate therapeutic development and ensure properly powered clinical trials. In addition, measurement of dystroglycan in muscles represents a potential muscle biomarker that could be used in early phase clinical trials as a measure of target engagement. The clinical utility of changes in dystroglycan has not been validated in human samples.
|Study Type :||Observational|
|Actual Enrollment :||101 participants|
|Official Title:||Biomarker Development in LGMD2i|
|Actual Study Start Date :||December 1, 2019|
|Actual Primary Completion Date :||October 10, 2022|
|Actual Study Completion Date :||October 10, 2022|
- 10-Meter walk (10 MWT) -mobility [ Time Frame: Through study completion at 12 months ]
The 10 MWT will be used to determine the ambulatory Cohort for of all subjects. For the purposes of this study, the definitions for ambulation are as follows:
- Cohort A: completes the 10 MWT unaided in ≥ 4 to ≤ 12 seconds
- Cohort B: completes the walk unaided in > 12 seconds or is non-ambulatory
- 100-Meter Timed Test (100m) - mobility [ Time Frame: Through study completion at 12 months ]The 100m timed test is designed to capture maximal ambulatory capacity. The participant will be asked to complete 4 full laps around 2 cones set 25 meters apart as quickly and as safely as possible, including running if able. This will not be assessed in participants with a 10-meter walk time greater than 12 seconds.
- NSAD- Motor performance [ Time Frame: Through study completion at 12 months ]North Star Assessment for Dysferlinopathy (NSAD) is a functional scale specifically designed to measure motor performance in individuals with LGMD. It consists of 29 items that are considered clinically relevant items from the North Star Ambulatory Assessment and the Motor Function Measure 20 with a maximum score of 54 and higher scores indicate higher functional abilities.
- Timed up-and-go (TUG) - mobility [ Time Frame: Through study completion at 12 months ]The TUG is an assessment used to evaluate functional ambulation, balance, and fall risk. The fastest time to rise from a chair, walk 3 meters, and return to sitting independently without an assistive device will be recorded. This will not be assessed in Cohort B participants.
- FVC - Pulmonary function [ Time Frame: Through study completion at 12 months ]The total amount of air exhaled during the forced expiratory volume test (Forced vital capacity - FVC) will be assessed in a sitting position only.
- Timed 4 stair Climb (4SC) - mobility [ Time Frame: Through study completion at 12 months ]The 4SC quantifies the time required for the participant to ascend 4 standard steps. This will not be assessed in participants with a 10 meter walk time greater than 12 seconds.
- 9 Hole Peg Test (9HPT) - distal upper extremity function [ Time Frame: Through study completion at 12 months ]The 9HPT is a quantitative measure of distal upper extremity function. It measures the time required for patients to place 9 pegs in the 9 holes on the board and then remove them as quickly as possible.
- Performance of Upper Limb (PUL 2.0) - limb function [ Time Frame: Through study completion at 12 months ]The PUL is a tool designed for assessing upper limb function in persons with neuromuscular disorders. It was developed as a conceptual framework reflecting the progression of weakness and natural history of functional decline in Duchenne muscular dystrophy (DMD). There are 22 scored items; a score of 42 indicates the highest level of independent function and 0 the lowest.
- Hand Held Dynamometry (HHD) - isometric strength [ Time Frame: Through study completion at 12 months ]HHD using the MicroFET2 myometer will be utilized to capture isometric strength in target muscle groups. Maximum strength in kilograms will be reported for each muscle group provided a continuous scale variable for analysis.
- To develop clinical outcome assessments for LGMD2i [ Time Frame: Through study completion at 12 months ]To determine the sensitivity of the COAs to longitudinal disease progression
- To validate potential biomarkers [ Time Frame: Baseline, Month 6 ]
To develop a reliable measure of dystroglycosylation in human skeletal muscle by using fresh tissue biopsy.
A muscle biopsy will be collected at baseline and 6 months from the right tibialis anterior. The biopsy site will be uniform between investigators. The investigators will utilize a 14-gauge Supercore biopsy instrument to take a total of three aspirations from the same site.
- To understand the change from baseline in muscle mass using Magnetic Resonance Imaging [ Time Frame: Baseline, Month 6, Month 12 ]To understand the change from baseline in muscle mass using Magnetic Resonance Imaging
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||10 Years to 65 Years (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Probability Sample|
- Age between 10-65 at enrollment
- Clinically affected (defined as weakness on bedside evaluation in either a limb-girdle pattern, or in a distal extremity)
- A genetically confirmed mutation in FKRP (LGMD2i)
- Willing and able to give informed consent and follow all procedures and requirements
- Any other illness that would interfere with the ability to undergo safe testing or would interfere with interpretation of the results in the opinion of the site investigator.
- History of a bleeding disorder, platelet count <50,000, current use of an anticoagulant.
- Positive pregnancy test
- A 10-meter walk time of <4 seconds
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04202627
|United States, California|
|University of California Irvine|
|Irvine, California, United States, 92697|
|United States, Colorado|
|University of Colorado Anschutz Medical Campus|
|Aurora, Colorado, United States, 80045|
|United States, Florida|
|University of Florida|
|Gainesville, Florida, United States, 32610|
|United States, Iowa|
|University of Iowa|
|Iowa City, Iowa, United States, 52242|
|United States, Kansas|
|University of Kansas Medical Center|
|Kansas City, Kansas, United States, 66160|
|United States, Maryland|
|Kennedy Krieger Institute|
|Baltimore, Maryland, United States, 21205|
|United States, Missouri|
|Washington University School of Medicine|
|Saint Louis, Missouri, United States, 63110|
|United States, North Carolina|
|Charlotte, North Carolina, United States, 28207|
|United States, Ohio|
|Nationwide Children's Hospital|
|Columbus, Ohio, United States, 43205|
|United States, Virginia|
|Virginia Commonwealth University|
|Richmond, Virginia, United States, 23298|
|Copenhagen Neuromuscular Center|
|Principal Investigator:||Nicholas E Johnson, MD||Virginia Commonwealth University|
|Responsible Party:||ML Bio Solutions, Inc.|
|Other Study ID Numbers:||
|First Posted:||December 17, 2019 Key Record Dates|
|Last Update Posted:||October 26, 2022|
|Last Verified:||October 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
ML Bio Solutions
Limb Girdle Muscular Dystrophy
Limb girdle muscular dystrophy type R9 (LGMD R9)
Muscular Dystrophies, Limb-Girdle
Muscular Disorders, Atrophic
Nervous System Diseases
Genetic Diseases, Inborn